(Tromsø 29. August 2017) Biotec Pharmacon ASA's (OSE:BIOTEC) subsidiary Biotec
BetaGlucans AS has today prolonged a supply agreement with an existing feed
customer for deliveries of its beta-glucan product M-Glucan® for use in animal
health
Deliveries under the agreement will continue from this day and run until 30th
June 2018 with 6 months renewal option. Expected revenues for the first period
is around NOK 25 million depending on their sales.
"We are very pleased to prolong this agreement as it secures substantial sales
within animal feed. It confirms Biotec's position as a market leader within
sales of beta-glucan products to animal health, says Svein W. F. Lien, CEO,
Biotec Pharmacon.
For additional information:
Børge Sørvoll
CFO
+47 952 90187
borge.sorvoll@biotec.no
About Biotec Pharmacon ASA:
Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and
ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel
immunomodulating products, including Woulgan®, a premium priced product in the
advanced wound care market. ArcticZymes develops, produces and markets enzymes
of marine origin used in molecular DNA technologies and diagnostics.